Lannett reports 5 generics launches in recent months
Lannett unveiled five products in the quarter ended Sept. 30, the company announced recently. Launches in the past several months included methylphenidate ER Capsules, the authorized generic equivalent of Metadate CD; esomeprazole DR capsules; buprenorphine plus naloxone sublingual tablets; and two pain management products.
The five products have a market value of approximately $1.6 billion, according to IQVIA, although actual generic market values are expected to be lower, according to the company.
From Jan. 1 to June 30, the company launched seven new products.
Earlier this year, the company acquired Metadate CD from UCB.
"Adding products to our offering is a key component of our growth plan," Lannett CEO Tim Crew said. "We still have as many as 20 products, of which eight have already received FDA approval, that we anticipate we will launch over the next 12 months. In addition, we are in active discussions to acquire and/or in-license products from various partners. Thus, our goal is to maintain this recent cadence of product launches for the foreseeable future."
The five products have a market value of approximately $1.6 billion, according to IQVIA, although actual generic market values are expected to be lower, according to the company.
From Jan. 1 to June 30, the company launched seven new products.
Earlier this year, the company acquired Metadate CD from UCB.
"Adding products to our offering is a key component of our growth plan," Lannett CEO Tim Crew said. "We still have as many as 20 products, of which eight have already received FDA approval, that we anticipate we will launch over the next 12 months. In addition, we are in active discussions to acquire and/or in-license products from various partners. Thus, our goal is to maintain this recent cadence of product launches for the foreseeable future."